A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants

Inclusion Criteria Participants who meet all of the following criteria will be eligible to participate in this study: * Between 18 and 75 years old. Both men and women can participate, but women may make up to 70% of the participants. * BMI of 30 or higher, or a BMI between 27 and 30 with at least one related health condition such as prediabetes, high blood pressure, abnormal cholesterol levels, fatty liver, or sleep apnea due to being overweight. * HbA1c level below 6.5% and fasting blood sugar levels below 126 mg/dL. * Have tried and failed to lose weight through diet and exercise at least once before the study and must have had a stable body weight (less than a 5% change) in the 90 days before the study. * Participants and their partners must not plan to become pregnant or donate sperm/eggs during the study and for 90 days after. They must agree to use effective contraception for at least 6 months prior to screening and continue their chosen contraception method throughout the study. Women who could become pregnant must have a negative pregnancy test 24 hours before the first dose of study drug. * Willing to maintain a stable diet and exercise routine during the study and keep a diary of their activities. * Understand the study procedures, be willing to follow the study rules strictly, and sign a consent form voluntarily. Exclusion Criteria Participants who meet any of the following criteria will be excluded from this study: * Known or suspected hypersensitivity to GLP-1 receptor agonists or similar products. * Took part in another clinical study and received treatment within the last 90 days or within 5 drug elimination half-lives. * Any type of diabetes. * Obesity caused by hormonal or genetic issues such as thyroid problems, Cushing's syndrome, or other specific conditions. * Have had or plan to have obesity treatment surgery or use weight loss devices, with some exceptions if done over a year ago. * Have used certain medications or therapies for weight loss or conditions affecting weight, including GLP-1 receptor agonists and other related drugs, within the last 90 days. * Recent serious heart problems, uncontrolled high blood pressure, or certain ECG abnormalities. * History of pancreatitis, gallbladder disease (except for those treated with cholecystectomy), or evidence of hypothyroidism (except for participants who have normal thyroid function at screening and have been on a stable dose thyroid replacement for at least 90 days and are expected to maintain a stable dose during the study) or hyperthyroidism or thyrotoxicosis. * History of cancer in the last 5 years, except for localized basal or squamous skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer. * Serious gastrointestinal diseases or surgeries that affect drug absorption. * Active liver disease, excluding nonalcoholic fatty liver disease. * Other serious health conditions that could increase study risk or make participation inappropriate, including certain psychiatric disorders. * Recent history of unexplained fainting or family history of long QT syndrome or sudden death. * History of organ transplant or severe autoimmune diseases. * Had major surgery within the last 6 months or plan to have surgery soon. * Significant abnormalities in kidney function, liver enzymes, blood tests, or other specified lab results. * Positive for hepatitis B, hepatitis C, or HIV. * Donated blood, lost a lot of blood, or received a transfusion in the last 90 days. * Exceed weekly alcohol intake limits or have a history of drug abuse (including cannabis, its derivatives, or any cannabis-containing products; except for prescribed drug for medical purpose). * Women who are pregnant or breastfeeding. * Any other disease, condition, or medication that the investigator believes would interfere with the study.